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TOL101 is a murine IgM mAb targeting the ab TCR.
Unlike other T cell targets, the ab TCR has no known
intracellular signaling domains and may provide a
nonmitogenic target for T cell inactivation. We report
the 6-month Phase 2 trial data testing TOL101 in kidney
transplantation. The study was designed to identify a
dose that resulted in significant CD3 T cell modulation
(<25 T cell/mm3), to examine the safety and tolerability
of TOL101 and to obtain preliminary efficacy informa-
tion. Thirty-six patients were enrolled and given 5–10
daily doses of TOL101; 33 patients completed dosing,
while three discontinued after two doses due to a self-
limiting urticarial rash. Infusion adjustments, antihist-
amines, steroids and dose escalation of TOL101
reduced the incidence of the rash. Doses of TOL101
above 28mg resulted in prolonged CD3 modulation,
with rapid recovery observed 7 days after therapy
cessation. There were no cases of patient or graft loss.
Few significant adverse events were reported, with
one nosocomial pneumonia. There were five biopsy-
confirmed acute cellular rejections (13.9%); however,
no donor-specific antibodies were detected. Overall
TOL101 was well-tolerated, supporting continued
clinical development using the dose escalating 21–
28–42–42–42mg regimen.
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Introduction
Despite dramatic advances in clinical immunosuppression, a
persistent goal in kidney transplantation remains the control
of alloimmunity while minimizing the toxicities of immuno-
suppressive agents. Prophylaxis against T cell–mediated
(cellular) acute rejection involves inhibition of alloreactive ab
T cells immediately following or within the first few weeks
after engraftment (1–3). Contemporary maintenance immu-
nosuppressive agents such as calcineurin inhibitors (cyclo-
sporine, tacrolimus), mammalian target of rapamycin
inhibitors (sirolimus, everolimus), anti-proliferative agents
azathioprine, mycophenolate mofetil (MMF) or mycophe-
nolic acid and agents capable of altering costimulation
pathways (humanized IgG/CTLA4 fusion protein; belata-
cept) have all combined to provide effective tools to prevent
rejection (4–6). In addition, the use of antibody induction
therapy not only appears to decrease the severity and rate of
acute rejection but also permits a delayed introduction and
minimization of potentially nephrotoxic maintenance thera-
py and may improve outcomes (7–9). Prophylactic (induc-
tion) antibody agents include rabbit or equine anti-
thymocyte globulin (ATG), anti-IL-2 receptor antibody
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(basiliximab), anti-CD52 (alemtuzumab) and the recently
discontinued murine anti-CD3 antibody OKT3 (10,11).
While the use of induction agents has significantly increased
over the past decade, questions remain regarding the
efficacy of anti-IL-2 receptor antibody and the risk/benefit
balance of depletional agents. In patients with higher
immunological risk, depletional therapies including ATG
and alemtuzumab are typically utilized (11–13). These agents
lead to prolonged mononuclear cell depletion, which is
desirable under conditions of increased risk of rejection but
may lead to untoward effects such as enhanced susceptibil-
ity to infection as well as the development of malignancy.
They are also occasionally associatedwith a number of drug-
related adverse events (AE) such as infusion reactions, and a
first dose cytokine release syndrome characterized by IL-6
and tumor necrosis factor (TNF) release (14). Utilization is
also limited in some cases in the acute setting by the
development of thrombocytopenia, and in the chronic
setting by the development of anti-drug antibodies (15).
While the nondepleting anti-IL-2 receptor antibody basilix-
imab is associated with reduced side effects, its efficacy is
not well defined under modern immunosuppression and is
notably inferior to depletional agents when immune
suppression minimization or steroid avoidance is at-
tempted (13,16). Therefore, its use is usually restricted to
patients at low risk for transplant rejection. Given the diverse
spectrum of immunological risk profiles among kidney
transplant recipients, there exists a therapeutic gap for an
induction agent that rapidly and reliably modulates the T cell
response but avoids long-term lymphodepletion.
Targeting the ab TCR has been shown to be highly
efficacious in animal models of transplantation and
autoimmunity (17–20). Additionally, outcomes with prede-
cessor anti-ab agents in human studies not only suggest a
reduced AE profile but also displayed similar efficacy to
muromonab-CD3 (21–23). TOL101 is a murine IgM mAb to
the ab TCR under study as a T cell–modulating agent.
Unlike predecessor anti-TCR agents including muromonab-
CD3 and humanized monoclonal anti-CD3 IgG agents that
targeted the CD3 subunit of the TCR, the novel targeting of
TOL101 to the ab subunits of TCR has the potential to
modulate T cells without mitogenicity, since the ab TCR
has no known intracellular signaling domains.
In order to determine the safety and immunomodulatory
effects of TOL101 as well as gather preliminary data
regarding the efficacy of TOL101 in the prevention of acute
T cell–mediated rejection, a first-in-human Phase 2 study of
TOL101 as an induction agent for primary kidney transplant
recipients was performed in 36 subjects, reported herein.
Methods
TOL101 development
TOL101 is an optimized version of the murine anti-human ab TCR antibody
originally named T10B9. This next-generation anti-ab TCR antibody has two
nucleotide mutations and a different glycosylation pattern to T10B9. In
addition, the manufacturing process has been optimized, incorporating
serum and animal-free components. TOL101 has been assigned a new IND
#104,594.
Study design
This Phase 2 study sponsored by Tolera Therapeutics, Inc. (Kalamazoo, MI)
was an open label, multicenter, first-in-human study designed to investigate
the safety, preliminary efficacy and immunogenicity of TOL101 administered
to primary kidney transplant recipients. The study was designed with a
modified adaptive design, including an initial dose-escalation component.
Subjects were enrolled from November 2010 until December 2012,
ClinicalTrials.gov identifier NCT01154387.Denovo renal transplant recipients
(n¼36) were enrolled into successively higher dose levels with the goal of
identifying two potentially therapeutic dose levels to be evaluated further in
Phase 3. The initial dose levels started a one-tenth (0.28mg) of theminimum
anticipated biologic effect level (MABEL) of 2.8mg. The follow-up periodwas
6months for all 36 enrolled patients. GoodClinical Practice andDeclaration of
Helsinki ethical principles were followed throughout the study. Institutional
ReviewBoard approvalwas obtained at all participating centers,with patients
receiving written informed consent upon enrollment. The sponsor, Tolera
Therapeutics, monitored safety, with an independent data safety monitoring
board (DSMB) used to provide safety oversight and to provide guidance on
each cohort for dose escalation. Serious events and opportunistic infections
were both investigator reported and confirmed by an independent monitor
that reviewed the medical records of each enrolled patient.
Eligibility criteria
Eligible patients were aged 18–60 years and scheduled to receive a primary
non-HLA identical kidney transplant from a living donor or standard criteria
deceased donor, with cold ischemia time of <30 h. In the last cohort, two
expanded criteria deceased donor (ECD) kidneys were enrolled. Only
patients with a history of Epstein-Barr virus (EBV) exposure (positive IgG
serology) and a panel reactive antibody of<20%were included in the study.
Patients were excluded from participation if they had prior organ
transplantation, positive flow cytometry T cell cross-match, an ABO-
incompatible donor, white cell count <2000/mm3, platelet count
<100 000/mm3, absolute neutrophil count<1000/mm3, liver transaminases
three times the upper normal value, HIV infection, hepatitis B or C virus
infection. X-ray confirmed chest inflammation; co-morbid conditions thought
to represent excessive risk or known hypersensitivity to rodent proteins or
other protocol required medications.
Maintenance immune suppression
Maintenance immunosuppression consisted of MMF, tacrolimus and
tapering steroids. Oral or intravenous (IV) MMF (minimum 750mg twice
daily) was initiated on the day of transplant. Tacrolimus was initiated orally
between Study Day 1 and Day 6, at the discretion of the investigator. The
starting dose of tacrolimus was 0.1–0.2mg/kg/day in divided doses.
Subsequent doses of tacrolimus were individualized to maintain whole
blood C0 levels in the range of 6–15 ng/mL for the first month posttransplant.
Tacrolimus C0 level measurements were done daily during TOL101
administration, weekly, Month 1 and on Days 90 and 180. The initial
corticosteroid dose was 500mg IV methylprednisolone at transplantation;
250mg on Day 1; 125mg on Day 2; 60mg Day 3; then oral prednisone
0.5mg/kg fromDay 4; tapered to 5–10mg/day byMonth 1 and to5mg/day
at Day 45 until Month 6.
Anti-infective prophylaxis
Oral valganciclovir (Valcyte1); Genentech, So. San Francisco, CA was
recommended at starting dose of 450mg within first 3 days of transplant in
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cytomegalovirus (CMV)þ recipients or in recipients of kidneys from CMVþ
donor, to be given daily for 6 months in those DþR, and 3 months in the
others. Oral trimethoprim/sulfamethoxazole (Septra SS1/Bactrim1) was
required for 6 months for prophylaxis of Pneumocystis carinii pneumonia,
and fungal prophylaxis per institution standard of care.
TOL101 administration and pharmacodynamics
TOL101 was provided in 14mg lyophilized vials (Tolera Therapeutics, Inc.).
Subjects received at least six daily doses of TOL101, beginning in the
operating room on Day 0 through a central venous catheter. Initial infusions
were administered over 1–2 h, and all subjects received 50mg IV
diphenhydramine and their daily methylprednisolone dose within 1 h of
the first three TOL101 doses. Using CD3 T cell count as the primary marker
of efficacy, this studywas designed to test ascending doses of TOL101. Due
to the potential immune stimulatory capacity of TCR targeting antibodies,
the initial TOL101 dose used was one-tenth of the MABEL, which was
determined to be 0.28mg. The precise dosing regimens in successive
cohorts were Group 1: 0.28mg (n¼ 2); Group 2: 2.4mg (n¼ 2); Group 3:
7mg (n¼ 2); Group 4: 14mg (n¼ 2); Group 5: 28mg (n¼ 6); Group 6: 32mg
(n¼ 4); Group 7: 42mg (n¼ 4) and two dose-escalation cohorts. The first
dose-escalating cohort Group 8: (n¼ 6) tested 14mg at Day 0, 21mg at Day
1, 28mg at Day 2, 42mg at Day 3 and 42mg at Day 4, with 42mg
administered daily until target tacrolimus levels were achieved. The second
dose-escalating cohort Group 9: (n¼ 8) tested 21mg at Day 0, 28mg at Day
1, 42mg at Day 2 and 42mg at Day 3 and 42mg until target tacrolimus levels
were achieved. A 24-h hold between patients and regular DSMB review of
patient data were performed as further safety precautions. A dose was
considered to be efficacious if CD3 counts were <25 T cells/mm3
throughout the dosing interval. Cessation of TOL101 was determined after
a minimum of six doses, if the tacrolimus C0 levels were therapeutic (8–
15 ng/mL).
End points
Safety parameters: Multiple safety parameters were monitored.
Events were classified by organ system as AE or serious adverse events
(SAE) according to the Medra dictionary using Good Clinical Practice
guidelines (http://www.who.int/medical_devices/innovation/MedDRAintro-
guide_version14_0_March2011.pdf). Subjects who suffered the same event
more thanoncewere recordedassufferingoneevent.Subjectswhohadmore
thanoneAEwithinasystemorganclasswerecountedonlyonce inthatsystem
organclass. Immunesafetyparameters includingsymptomsthatmaysuggest
cytokine release syndrome were carefully monitored. Cytokine release
syndrome was identified using a constellation of three observations
after infusion, namely a fever greater than 1018 Fahrenheit, combined with
rigor (shakingchills) andshortnessof breath. Serum levels ofTNF, interferon-g
(IFN-g), IL-2, IL-6 and IL-10were determined at 0, 2, 8 and 24 h after the first
dose, as well as upon recognition of an infusion reaction involving fever,
chills, rigors, skin disorders or shortness of breath. Cytokines were
measured by PRL laboratories (Overland Park, KS) using Luminex
technology (Austin, TX). Nitric oxide (NO) levels were also determined
using calorimetric assay by ABC Laboratories (Columbia, MI) at 0, 2, 8 and
24 h after the first dose as well as on Day 4. Human anti-mouse antibody
(HAMA) was determined at baseline, Day 14 and Day 28, using sandwich
enzyme-linked immunosorbent assay (ELISA) with TOL101 as the capture
antibody (ABC Laboratories).
The incidence of malignancies including lymphoproliferative disorder was
collected from clinical records. Screening for CMV (Days 28, 90 and 180), BK
virus (BKV) (Days 90 and 180) and EBV (Days 28, 90 and 180) was performed
using blood polymerase chain reaction detection. The incidence of other
serious or opportunistic infections was also recorded.
Efficacy parameters: Clinical efficacy was determined by the pharmaco-
dynamic (PD) effect of TOL101 on CD3þ T lymphocyte counts. Successful T
cell modulation was considered present in patients with sustained daily
CD3þ T cell numbers below 25 CD3þ counts/mm3 for the continuous
dosing interval. In addition, the triple end point of patient survival, graft
survival and biopsy-confirmed acute rejection (BCAR) at any time during the
6 months was determined. Protocol biopsies were not required. Delayed
graft function was defined as the need for dialysis within the first week
posttransplant. Renal function was determined by estimated GFR (eGFR) at
each study visit (MDRD method), with measured GFR determined by
iothalamate clearance at Day 180/end of study (EOS). The spot urine protein
to creatinine ratio as well as donor-specific antibody (DSA) was measured at
Day 90 and Day 180/EOS.
CD3 counts
Flow cytometry was used to determine CD3 counts and the impact of
TOL101 on memory and na€ıve T cell subsets. Blood samples were collected
daily in the morning within 1–2 h of the next TOL101 dose in sodium heparin
tubes and shipped overnight to a central flow cytometry facility (Neo-
Genomics Laboratories, Irvine, CA), with CD3 counts determined using the
Beckman Coulter (Brea, CA) CD3 flow cytometry kit on whole blood
samples.
Pharmacokinetics
Serum concentrations of TOL101 were measured at 0, 2, 4, 8 and 24 h after
administration of Dose 1 (Day 0), Dose 4, the last dose, and on Day 14. An
ELISA for murine mouse IgM was utilized (ABC Laboratories). A one-
compartment IV infusion model was used and fit using Phoenix WinNonlin
Version 6.2 (Certara, St. Louis, MO) and data were weighted by 1/Yhat,
where Yhat is the predicted plasma concentration at each time.
Statistics
The number of subjects per cohort was not based on statistical
considerations but intended to provide safety and PD data sufficient to
escalate to the next dose level. Frequency tables have been presented for all
infections, AEs, all AEs by maximum severity, drug-related AEs, SAEs and
AEs resulting in study drug discontinuation. For quantitative laboratory tests,
summary statistics are presented at each time point. Both measured and
eGFR are summarizedwith descriptive statistics. Delayed graft function and
episodes of BCAR are summarized in frequency tables. For the urine protein
to creatinine ratio and the DSA assessments, summary statistics will be
presented for the values obtained at Day 90 and Day 180/EOS.
Results
Patient characteristics
Patient enrollment began in February 2010 and ended in
December 2012 with 13 US centers participating. A total of
36 patientswere enrolled into this Phase 2 study, including a
broad cross-section of patients (Table 1). The mean donor
agewas 40 years,with 28 living and 8 deceased donors. The
mean recipient age was 44 years, with 75%male. The final
dose-escalation cohorts included eight deceased donor
transplants, two ECD donor kidneys and four African
American recipients, with HLA mismatch being on average
greater than 4. Themost common causes of end-stage renal
disease were glomerular diseases (38%) and polycystic
kidney disease (25%).
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Serious adverse events
For the entire study, 27 SAEs were reported in 12 subjects
(Table S1). No deaths were observed. All but one SAE was
considered to be ‘‘unrelated’’ to study drug. The ‘‘poten-
tially related’’ SAE was nosocomial pneumonia on POD 18
in a 42-year-old male. Hewas hospitalized with a cough and
persistent chest X-ray infiltrate, but no organisms were
cultured from blood or sputum. He was given antibiotics
and the pneumonia resolved in 2 weeks. Otherwise, most
other SAEs were commonly associated with transplant
surgery and other non-TOL101-related issues.
Adverse events
For the entire study, a total of 653 AEs were reported in 36
subjects including 47 AEs in 22 subjectswhowere reported
to be ‘‘possibly,’’ ‘‘probably’’ or ‘‘definitely’’ related to
TOL101. All reported AEs regardless of causality observed
in 10% of patients are shown in Table 2. The majority of
AEswere reported in 28, 32, and 42mgdose cohorts. Three
subjects discontinued drug due to a drug-related AE (rash),
all in the 42mg dose group. The most commonly reported
study drug-related AE observed in 11 (30%) of patients was
a skin rash, which was variably described as urticarial, red,
raised, hives and/or wheal like. The rash appeared on the
trunk, abdomen and/or the extremities (Figure 1) and
usually began at the end of the first or second infusion of
TOL101 or a few hours thereafter (Tables 2 and 3). The rash
resolved in all cases within a few hours spontaneously, or
by the next day after treatment with additional diphenhy-
dramine and acetaminophen. In no case was the rash
necrotic or persistent, and it never progressed to more
severemanifestations. The rashwasmost intense and only
recurred in the initial 42mg cohort. This led to the protocol
of stepwise increases in the initial doses of TOL101 (the
dose-escalating cohorts) and a prolongation of the infusion
time to 6 h for the first two doses. This approach allowed for
42mg dosing with reduced rash incidence. In the final
cohort dose regimen of Day 0 (21mg), Day 1 (28mg), Day 2
(42mg), Day 3 (42mg) and Day 4 (42mg), there was one
transient rash, which occurred with inadvertent rapid
infusion of the first dose (Table 3).
Infections and malignancies
Posttransplant infections observed during the study are
presented in Table 4. Only one significant infection was
considered potentially associated with TOL101: nosocomi-
al pneumonia detected on chest X-ray. However, no culture
was taken from this patient and as such a definitive
diagnosis and causative agent cannot be established.
Bacterial skin infections were described as incisional
wound cellulitis or drainage, with one case of folliculitis
reported. Five cases (13.9%) of BKV viremia were reported
on protocol viral surveillance at 3 and 6 months. They were
treated by immunosuppressive dose reduction according to
local practice. There was one case (2.8%) of histologically
confirmed BKV associated nephropathy (Patient 8-005).
These six cases (16.7%) were spread across three dosing
cohorts: Group 4, 14mg¼ 1; Group 6, 32mg¼ 2 and Group
8, dose-escalating chort 14–42mg¼ 3, and as such a dose–
response is not directly apparent. One case of CMV viremia
with colitis occurred at Day 169. No EBV or pneumocystis
pneumonia was observed. No malignancies have been
reported to date in subjects who received TOL101.
Cytokine release and anti-drug antibody detection
As noted in the AE tables, symptoms associated with
cytokine release syndrome were not observed. The lack of
symptoms was supported by the low levels of IFN-g, TNF,
IL-2, IL-6 and IL-10 at baseline and 0, 2, 4, 8 and 24h after
Table 1: Demographics (N¼36)
Recipients Donors
Age at transplant, mean (years) 44.4 40.5
Height (cm) 177.2 N/A
Weight (kg) 91.58 N/A
BMI (kg/m2) 29.47 N/A
Gender, n (%)
Male 27 (75) 15 (41.7)
Female 9 (25) 21 (58.3)
Ethnic origin, n (%)
White 27 (75) 21 (75)
Black 6 (16) 5 (18)
Asian 1 (2.8) 1 (3.5)
Other 1 (2.8) 1 (3.5)
Cause of renal failure, n (%)
Hypertensive nephrosclerosis 5 (13.9) N/A
Diabetes 5 (13.9) N/A
Polycystic kidney disease 9 (25) N/A
Glomerulonephritis 1 (2.8) N/A
Focal segmental glomerulonephritis 3 (10.7) N/A
IgA nephropathy 5 (17.9) N/A
Other 8 (22.2) N/A
Type of donor, n (%)
Living, related N/A 13 (46.4)
Living, unrelated N/A 15 (41.6)
Deceased N/A 8 (22.2)
Blood type, n (%)
A 15 (41.7) 11 (30.5)
B 3 (8.3) 4 (11.1)
AB 3 (8.3) 1 (2.7)
O 15 (41.7) 20 (55.5)
HLA mismatch, n (%)
0 0 (0) N/A
1 2 (5.5) N/A
2 2 (5.5) N/A
3 32 (88.9) N/A
Panel-reactive antibody at baseline
Mean (%) 3.4 N/A
20, n (%) 1 (2.8) N/A
Cold ischemia time
Mean (min) 330 N/A
Pretransplant CMV antibody match, n (%)
Donorþ/recipient 8 (22.2) N/A
Donorþ/recipientþ 10 (27.8) N/A
Donor/recipient 13 (36.1) N/A
Donor/recipientþ 5 (13.9) N/A
CMV, cytomegalovirus.
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infusion, respectively (Figure 2A–E). Furthermore, another
potential inflammatory marker indicative of infusion reac-
tions includes the production of NO, which was not
significantly detected in TOL101-treated patients during
or after infusions on Days 0 and 4. The mean percent
change from baseline NO levels in micromolar during
infusion, end of infusion and 2 h. Postinfusion were24%,
Table 2: Adverse events (all causality) >10% in any treatment
group, N¼36
Adverse event Patients, n (%)
All 36 (100)
Blood and lymphatic disorders
Total 14 (38.9)
Anemia 5 (13.9)
Leukopenia 6 (16.7)
Cardiac disorders
Total 9 (25)
Tachycardia 6 (16.7)
Eye disorders
Total 4 (11.1)
Vision blurred 4 (11.1)
Gastrointestinal disorders
Total 31 (86.1)
Abdominal distention 4 (11.1)
Abdominal pain 5 (13.9)
Constipation 16 (44.4)
Diarrhea 16 (44.4)
Nausea 20 (55.6)
Vomiting 10 (27.8)
General disorders and administration site disorders
Total 24 (66.7)
Chills 4 (11.1)
Fatigue 10 (27.8)
Edema peripheral 9 (25)
Pain 4 (11.1)
Injury, poisoning and procedural complications
Total 33 (91.7)
Incision site pain 26 (72.2)
Procedural pain 7 (19.4)
Investigations
Total 19 (52.8)
Blood creatinine increased 5 (13.9)
Vitamin D decreased 4 (11.1)
Metabolic and nutritional disorders
Total 28 (77.8)
Dehydration 4 (11.1)
Diabetes mellitus 4 (11.1)
Gout 4 (11.1)
Hyperglycemia 12 (33.3)
Hyperkalemia 5 (13.9)
Hyperlipidemia 5 (13.9)
Hypokalemia 7 (19.4)
Hypomagnesemia 20 (55.5)
Hypophosphatemia 11 (30.6)
Musculoskeletal and connective tissue disorders
Total 12 (33.3)
Back pain 5 (13.9)
Nervous system disorders
Total 23 (63.9)
Dizziness 4 (13.1)
Headache 6 (16.7)
Tremor 14 (38.9)
Psychiatric disorders
Total 8 (22.2)
Insomnia 5 (13.9)
Renal and urinary disorders
Total 12 (33.3)
Hematuria 6 (16.7)
Reproductive system
Table 2: Continued
Adverse event Patients, n (%)
Total 5 (13.9)
Scrotal edema/pain 4 (11.1)
Respiratory, thoracic and mediastinal disorders
Total 15 (41.7)
Cough 5 (13.9)
Dyspnea 4 (11.1)
Oropharyngeal pain 6 (16.7)
Skin and subcutaneous tissue
Total 23 (63.9)
Pruritus 11 (30.6)
Urticaria 6 (16.7)
Surgical and medical procedures
Total 4 (11.1)
Incisional drainage 4 (11.1)
Vascular disorders
Total 18 (50)
Hypertension 11 (30.6)
Hypotension 7 (19.4)
Adverse event coding was done using the MedDRA Version 13.1
dictionary (http://www.who.int/medical_devices/innovation/Med-
DRAintroguide_version14_0_March2011.pdf). Subjects who have
the same event more than once are counted only once for the
preferred term. Subjects who have more than one adverse event
within a system organ class are counted only once in that system
organ class. Date produced: October 18, 2013.
Figure 1: Post-TOL101 rash on trunk and abdomen after initial
dose. In some cases, TOL101 infusion was associated with a
urticarial rash. This is an example of the urticarial rash on the trunk
and abdomen of a 22-year-old male treated with 50 mg
diphenhydramine and 650 mg acetaminophen.
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2%,19%,þ12%,31%andþ4% for cohort Groups 4–
9, respectively. Low titer HAMA (1/100) was detected in
only 1/36 (2.8%) patient on Day 28. No high-titer HAMA (1/
1000) was ever detected.
Efficacy as measured by CD3 count reduction
Peripheral blood CD3 T cell counts were measured daily in
the morning within 1–2 h of the next TOL101 infusion.
During TOL101 treatment, dosing of TOL101 was required
for a minimum of 5 days (six doses), with continued dosing
until therapeutic tacrolimus levels were reached (8–15 ng/
mL). In seven patients, further doses were needed. In all
patients, a primary reduction in leukocyte counts, including
CD3 expressing cells was observed immediately after
transplant, a potential result of IV steroid infusion (24).
Within 48–72 h circulating CD3 counts increased above the
25/mm3 target in patients receiving 0.28, 2.4, 7 and 14mg
TOL101 (Figure 3A). In the 28mg cohort, CD3 counts
remained mostly under 25/mm3, with the exception of one
patient who experienced a spike in CD3 numbers on Day 3
(Figure 3B). While 28mg appeared to be a promising dose
Table 3: Urticarial rash incidence; red cells denote TOL101 dose at time of rash
Treatment 
Group Patient Dose 1 Dose 2 Dose 3 Dose 4 Dose 5 Dose 6 Dose 7 Dose 8 
0.28 mg 
06-001 
                
08-001 
                
1.4 mg 
02-001 
                
04-001 
                
  
02-002 
                
7.0 mg 04-002 
                
  
05-001 
                
14.0 mg 08-002 
                
28.0 mg 
01-001 
                
04-003 
                
07-001 
                
03-001 
                
07-0031 
                
07-004 
                
  
03-002
                
32.0 mg 08-004 
                
  
12-0011 
                
  
07-005 
                
42mg 
06-0021 
                
07-002 
                
04-004 
                
08-003 
                
Escalation 
Group 1 07-006 14mg 21mg 28mg 42mg 42mg 42mg    
14-42mg 07-007 14mg 21mg 28mg 42mg 42mg 42mg 
    
  07-008 14mg 21mg 28mg 42mg 42mg 42mg 
    
  08-0051 14mg 21mg 28mg 42mg 42mg 42mg 
    
 07-009 14mg 21mg 28mg 42mg 42mg 42mg 
    
  02-003 14mg 21mg 28mg 42mg 42mg 42mg 
    
Escalation 
Group 2 07-010 21mg 28mg 42mg 42mg 42mg 42mg 42mg 42mg 
21-42mg 07-011 21mg 28mg 42mg 42mg 42mg 42mg 42mg 42mg 
  07-012 21mg 28mg 42mg 42mg 42mg       
  07-013 21mg 28mg 42mg 42mg 42mg       
  02-004 21mg 28mg 42mg 42mg 42mg       
  03-003 21mg 28mg 42mg 42mg 42mg       
  03-004 21mg 28mg 42mg 42mg 42mg       
1
1Patients that had biopsy-confirmed acute rejection.
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regimen, this one outlier triggered escalation of TOL101 to
32 and 42mg. At both dosing regimens robust CD3
modulation was achieved; however, a rash was noted in
patients in the 32 and 42mg cohorts, respectively. To
address possible preformed T cell soluble mediator release
as a mechanism, two dose-escalation strategies were
tested to exhaust these stores at sub-symptomatic levels.
One strategy began at 14mg on Day 0 with the other at
21mg on Day 0. In each case, the dose was rapidly
escalated to 42mg by the third or fourth dose. The
utilization of a dose-escalating regimen not only reduced
the propensity for rash development but also resulted in
robust CD3 modulation, meeting the PD target.
The recovery of CD3 expression after TOL101 dosing was
observed to occur in all patients by Day 14 (Figure 3B). This
recovery combined with stable white blood cell counts
suggests the possibility of a nondepletional mechanism of
action. The mean plasma elimination half-life of TOL101 in
patients receiving greater than 28mg or in the dose-
escalating cohorts was 23.8 9 h, supporting once daily
infusions.
Efficacy composite triple end point
Therewere no patient deaths or graft losses reported in the
study, and five (13.9%) subjects experienced BCAR
episodes (Table 5). While no rejections occurred during
TOL101 treatment, their occurrence was relatively soon
after the drugwas completed onDays 10–20, and three had
a vascular component. The last tacrolimus trough blood
level (ng/mL) prior to each rejection was Day 10 (13.1),
Day 11 (7.8), Day 14 (6.3), Day 16 (7.6) and Day 20 (8.6). All
rejection episodes were treated with thymoglobulin (4) or
steroids (1), and resolved clinically without graft loss. No
Table 4: Infections and malignancies (N¼36)
Infections Patients, n (%)
Bacterial
Skin 5 (13.9)
Pneumonia 1 (2.8) nosocomial
Pharyngitis, rhinitis and sinusitis 5 (13.9)
Urinary tract 3 (8.3)
Urosepsis 1 (2.8) Escherichia coli
Viral (viremia)
CMV 2 (5.6)
BK 5 (13.9)
BK associated nephropathy 1 (2.8)
EBV 0 (0)
Fungal
Candida 0 (0)
Other 0 (0)
Opportunistic
Pneumocystis 0 (0)
Cancer
PTLD 0 (0)
Solid organ 0 (0)
CMV, cytomegalovirus; EBV, Epstein-Barr virus; PTLD, posttrans-
plant lymphoproliferative disorder.
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Figure 2: The production of cytokines after the first dose of TOL101. (A–E) The production of IFN-g (A), TNF (B), IL-2 (C), IL-6 (D) and IL-
10 (E) was measured 0, 2, 4, 8 and 24h after the first infusion of TOL101. No difference in cytokine responses was observed across dose
levels. The mean standard deviation are presented. IFN-g, interferon-g; TNF, tumor necrosis factor.
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donor-specific anti-HLA antibodies have been detected in
the 22 patients tested at both 3 and 6 months posttrans-
plant. Fourteen patients were not tested.
Kidney function
Two patientswho received ECD kidneys in cohort 9 (07-010
and 07-011; Table 3) required first week dialysis. In general,
kidney function was observed to improve throughout the
study with increases in eGFR observed in all patients (Day
180 mean eGFR being 54mg/dL) (Table 5). In addition, of
the 23 subjects who completed a measured (iothalamate)
GFR the mean was 65.7mL/min/1.73m2. A voided urine
protein to creatinine ratio was performed on Day 90 (n¼ 27)
and Day 180/EOS (n¼27). Excluding three patients due to
laboratory handling issues, ratios observed were
0.17 0.12 and 0.13 0.11, respectively (Table 5).
Discussion
Targeting the ab TCR with TOL 101 is hypothesized to
provide rapid and robust T cell modulation, low acute
rejection rates and reduced AE compared with currently
utilized induction agents. The results from this first-in-
human Phase 2 clinical trial investigating the safety and
efficacy of TOL101 in 36 primary renal transplant patients
are reported. In particular, advancing from subtherapeutic
to therapeutic dosing regimens did not result in diminished
clinical outcomes or untoward events. These data show
that TOL101 is a highly TCR-specific mAb capable of
providing robust T cell modulation, without inducing
significant cytokine release and/or other immunologic
toxicity.
TOL101was generally well tolerated across all groups,with
urticarial rash the only significant AE resulting in study drug
discontinuation in three subjects. Skin eruptions are
commonly reported side effects in patients receiving
biologics, and have been observed in some patients
receiving rabbit ATG, alemtuzumab and anti-CD3
agents (25). In the case of TOL101, rashwas not associated
with any hemodynamic effects, skin breakdown or long-
Figure 3: (A, B) Pharmacodynamic (CD3 absolute/mm3) responses to increasing doses of TOL101 over 5–9 days. Themean of each cohort
is presented.
Table 5: Efficacy observations: N¼36 (end of study 6 months)
End point N (%)
Patient survival 36 (100)
Graft survival 36 (100)
Treated BCAR 5 (13.9)
Banff scored
1A (Day 10) 1
1B (Day 16) 1
2A (Days 11, 14 and 20) 3
2B or 3 0
Graft function
Delayed graft function (all), n¼36 2 (5.6)
Delayed graft function (deceased donors),
n¼8
2 (25)
Estimated GFR (cc/min) (Day 180), n¼36 55.610
Measured GFR (cc/min/1.73m2) (Day 180),
n¼23
65.726
Urine protein/creatinine
(Day 90) 0.170.12
(Day 180) n¼27 0.130.11
Donor-specific antibody
n¼22 tested; 14 not tested
Day 90 0
Day 180 0
BCAR, biopsy-confirmed acute rejection.
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lasting sequelae. Cytokine release and anaphylaxis are
potential causes of rash; however, no patient in the current
study appeared to have any anaphylactoid like reaction. The
levels (pg/mL) of the examined pro-inflammatory cytokines
IFN-g, TNF, IL-2, IL-6 and IL-10 were relatively low in all
TOL101-treated patients (Figure 2A–E). In comparison,
infusion of rabbit ATG is accompanied by release at levels
of 1000–3000 pg/mL of these cytokines (14). While the
specific etiology of the rash is under further examination,
one possible explanation for the rash was T cell release of
preformed nonclassical soluble mediators with resultant
cutaneous vasodilation. As such a dose-escalation strategy
combined with a slower infusion rate was used to deplete
these potential granule stores. This was viewed to be
successful with patients receiving an escalating regimen of
21, 28, 42, 42 and 42mg experiencing minimal rash
symptoms, permitting the full infusion with the 42mg
dose.
Historically, other anti-ab TCR antibodies have been tested
in humans, namely T10B9 and BMA-031. Not only both
these agents showed promising efficacy, but their safety
profiles were also favorable, with less cytokine release
syndrome and serious infections reported compared to
muromonab-CD3 (21–23). However, the incidence and
intensity of HAMA formation after treatment were similar
to those recorded for muromonab-CD3. Unlike these
predecessor antibodies, whereby immunogenicity was a
major drawback, TOL101 utilization has been associated
with very little anti-drug antibody formation, a result of
different manufacturing processes and contemporary im-
mune suppression (15,25,26). In this Phase 2 trial, only 1/36
(2.8%) of treated recipients demonstratedHAMA formation,
a similar incidence to the chimerized IL-2 receptor blocker
basiliximab, 1.5% (27). This potentially makes ab TCR
blockade an attractive target for the pharmacologic control of
autoimmunity and transplant rejection (28).
This initial short-term (6-month) experience using TOL101
induction with tacrolimus, MMF and low-dose steroids in
clinical kidney transplantation demonstrated excellent patient
and graft survival with acceptable AE rates similar to
conventional therapies. Together these initial data show
TOL101 tobe relatively safe andhighly effective atmodulating
CD3þ T cells. This low to moderate risk population
experienced a BCAR rate of 13.9%, with the majority of
episodes occurring within the first 3 weeks of transplant. In
addition, TOL101 induction permitted stable renal function
and no reports of DSA development for up to 6 months. The
plasma elimination half-life of 23.8h permits once daily
administration, and the apparent recovery of circulating CD3 T
cells by 14 days suggests a narrower window of intense
immunosuppression thanother biologics. The rateof recovery
of TOL101 treated T cells and their function should be an
active area of future investigation. Finally, and when taken
together, these data support the initiation of larger Phase 3
studies testing TOL101 against thymoglobulin and basilix-
imab, using the final dose-escalating regimen (cohort 9).
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